Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bolland

Showing results (101-110 of 186) with videos related to

Pageof 19
Sort By:
Revue Medicale De Liege|November 26, 2004
[Spondylocostal dysostosis: a rare genetic disease]O Beine, J Bolland, A Verloes, et al.
BMJ (Clinical Research Ed.)|April 21, 2011
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysisMark J Bolland, Andrew Grey, Alison Avenell, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 26, 2004
Bilateral femoral head osteonecrosis after septic shock and multiorgan failureMark J Bolland, Gill Hood, Sonja T Bastin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 13, 2017
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trialAndrew Grey, Mark J Bolland, Anne Horne, et al.
Annals of Clinical Biochemistry|January 25, 2025
Biochemical osteomalacia in adults undergoing vitamin D testing in the North-East of ScotlandAngus D Macleod, Mark J Bolland, Andrew Balfour, et al.
Bonekey Reports|August 17, 2013
Subgroup analysis for the risk of cardiovascular disease with calcium supplementsLoretta T Radford, Mark J Bolland, Greg D Gamble, et al.
The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenAndrew Grey, Mark J Bolland, Diana Wattie, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 16, 2014
Mendelian randomization analysis to examine for a causal effect of urate on bone mineral densityNicola Dalbeth, Ruth Topless, Tanya Flynn, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 29, 2021
Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled TrialAndrew Grey, Mark J Bolland, Anne Horne, et al.
Annals of Clinical Biochemistry|May 18, 2006
A case of low cortisol-binding globulin: use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis testsJames S Davidson, Mark J Bolland, Michael S Croxson, et al.
Pageof 19

Showing results (101-110 of 186) with videos related to

Sort By:
Pageof 19
Revue Medicale De Liege|November 26, 2004
[Spondylocostal dysostosis: a rare genetic disease]O Beine, J Bolland, A Verloes, et al.
BMJ (Clinical Research Ed.)|April 21, 2011
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysisMark J Bolland, Andrew Grey, Alison Avenell, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 26, 2004
Bilateral femoral head osteonecrosis after septic shock and multiorgan failureMark J Bolland, Gill Hood, Sonja T Bastin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 13, 2017
Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trialAndrew Grey, Mark J Bolland, Anne Horne, et al.
Annals of Clinical Biochemistry|January 25, 2025
Biochemical osteomalacia in adults undergoing vitamin D testing in the North-East of ScotlandAngus D Macleod, Mark J Bolland, Andrew Balfour, et al.
Bonekey Reports|August 17, 2013
Subgroup analysis for the risk of cardiovascular disease with calcium supplementsLoretta T Radford, Mark J Bolland, Greg D Gamble, et al.
The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenAndrew Grey, Mark J Bolland, Diana Wattie, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 16, 2014
Mendelian randomization analysis to examine for a causal effect of urate on bone mineral densityNicola Dalbeth, Ruth Topless, Tanya Flynn, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 29, 2021
Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled TrialAndrew Grey, Mark J Bolland, Anne Horne, et al.
Annals of Clinical Biochemistry|May 18, 2006
A case of low cortisol-binding globulin: use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis testsJames S Davidson, Mark J Bolland, Michael S Croxson, et al.
Pageof 19